Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
May 2008

Three IM Antipsychotics
New intramuscular (IM) formulations of second-generation antipsychotics appear comparable and possibly superior in efficacy and safety to older agents, but are more expensive.

Baclofen for Alcohol Dependency with Liver Cirrhosis
Baclofen (Lioresal and others) shows efficacy in treating alcohol dependency with no adverse hepatic effects.

Antipsychotics to Treat Aggression in Patients with Intellectual Disability
A double-blind study finds little evidence to support the use of antipsychotics to treat aggression in patients with intellectual disability.

In Brief
Desvenlafaxine Approved for Depression; Olanzapine LAI Not Approved for Schizophrenia

Depression Infrequently Treated
Many patients with depression worldwide do not receive effective care.

Clozapine Plus Aripiprazole
Aripiprazole (Abilify) may be beneficial for patients with schizophrenia who respond only partially to clozapine (Clozaril and others).

In Brief

May 2008

In February, the US Food and Drug Administration (FDA) approved the new serotonin-norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (Pristiq) for the treatment of major depressive disorder in adult patients (Wyeth press release, February 29, 2008. Available at: http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressreleases/2008/1204331198948.html.…

To view the rest of this article, please: